Hikma continues buying spree with stake in China's Hubei Haosun
This article was originally published in Scrip
Hikma Pharmaceuticals of Jordan continues to strengthen its Asian presence, this time through the acquisition of a 'significant' minority interest in the privately-owned Chinese actives maker, Hubei Haosun Pharmaceutical.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…